<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333277</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 83541717.0.0000.5149</org_study_id>
    <nct_id>NCT04333277</nct_id>
  </id_info>
  <brief_title>Lactobacillus Helveticus in the Treatment of Major Depression</brief_title>
  <official_title>Double-blind Placebo-controlled Clinical Trial of Lactobacillus Helveticus as an add-on Strategy for the Treatment of Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Minas Gerais</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate whether the association of the probiotic
      Lactobacillus helveticus to standard antidepressant will contribute to the treatment of major
      depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with the diagnosis of major depression according to the Diagnostic and Statistical
      Manual of Mental Disorders (DSM-5) criteria will receive one daily oral dose of 1 × 10^9
      colony-forming units (CFUs) of Lactobacillus helveticus or placebo for 8 weeks in addition to
      conventional antidepressant treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the depressive symptoms severity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Depression symptoms severity will be assessed through the Montgomery-Asberg Depression Rating Scale (MADRS) (Minimum: 0 to 6 - normal/symptom absent/ Maximum: &gt;34 - severe depression). Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota composition</measure>
    <time_frame>8 weeks</time_frame>
    <description>Microbiota composition will be assessed by Real-Time qPCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the serum levels of biomarkers</measure>
    <time_frame>8 weeks</time_frame>
    <description>Inflammatory markers (adiponectin, resistin, leptin, TNF, IL6 and IL10) and neurotrophic factors (GDNF, NGF) will be assessed by enzyme-linked immunosorbent assay (ELISA). Markers will be measured in pg/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perception of stress</measure>
    <time_frame>8 weeks</time_frame>
    <description>Perception of stress will be assessed by Perceived Stress Scale (PSS). It is a measure of the degree to which life situations are assessed as stressful. Range from 0 to 40 with higher scores indicating worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with major depression (both sexes) will receive capsules with 1 × 10^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Patients with major depression (both sexes) will receive capsules with 1 × 10^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks</description>
    <arm_group_label>Maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 65 years old;

          -  Diagnosis of major depression

          -  Agree to sign the informed consent.

        Exclusion Criteria:

          -  Treatment with anti-inflammatory drugs or antibiotics of any pharmacological classes
             in the month before treatment enrollment;

          -  Use of dietary supplementation (herbal supplements, other pro- or prebiotics).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aline Silva de Miranda, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Érica Leandro Marciano Vieira</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lais Bhering Martins</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio L Teixeira, PhD</last_name>
    <phone>+1 713 486 2555</phone>
    <email>altexr@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Teixeira, PhD</last_name>
    <phone>+1 713 486 2555</phone>
    <email>altexr@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clínicas</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antônio L Teixeira, PhD</last_name>
      <phone>+55 31 3409-8073</phone>
      <email>altexr@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Minas Gerais</investigator_affiliation>
    <investigator_full_name>Antonio L Teixeira Jr</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

